Array BioPharma (ARRY) PT Raised to $9 at Leerink Partners Following 'Impressive' Phase III Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Stocks gear up for Big Tech earnings; yen toys with danger zone
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises on robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
Array BioPharma (ARRY) PT Raised to $8 at Jefferies
September 27, 2016 7:17 AM EDTJefferies analyst Eun Yang reiterated a Buy rating and raised his price target on Array BioPharma (NASDAQ: ARRY) to $8.00 (from $7.00) following successful Phase 3 COLUMBUS results yesterday.
Yang commented, "Given historical MEKi/BRAFi combo data in BRAFm melanoma, positive Ph3 COLUMBUS data is... More
Array Biopharma (ARRY) Adds to Gains; Shares Up 70%
September 26, 2016 2:03 PM EDTArray Biopharma (NASDAQ: ARRY) is pushing to the highs of the session. Shares are now up 70% after the company announced positive top-line results of the Phase III "COLUMBUS" trial evaluating the combination of binimetinib with encorafenib compared to Roche's vemurafenib in patients with BRAF+ metastatic melanoma.
... MoreArray BioPharma (ARRY) Could Trade up 50-75% Amid Positive COLUMBUS Trial Results - JPMorgan
September 26, 2016 9:43 AM EDTJPMorgan analyst Anupam Rama weighed in on Array BioPharma (NASDAQ: ARRY) after the company and partner Pierre Fabre announced positive results from phase 3 Columbus trial of encorafenib + binimetinib for the treatment of BRAF-melanoma. The analyst said the stock could trade up ~50-75% amid the results.
Rama... More
Array Biopharma (ARRY), Pierre Fabre Announce Encorafenib Combo Phase 3 Met Primary Endpoint in BRAF-Mutant Melanoma
September 26, 2016 7:01 AM EDTArray BioPharma (Nasdaq: ARRY) and Pierre Fabre jointly announced top-line results from Part 1 of the Phase 3 COLUMBUS (Combined LGX818 Used with MEK162 in BRAF Mutant Unresectable Skin Cancer) study evaluating LGX818 (encorafenib), a BRAF inhibitor, and MEK162... More
